Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder characterized by progressive muscle weakness and degeneration. It primarily affects males and usually becomes evident in early childhood. DMD is caused by a mutation in the dystrophin gene, leading to the absence of a crucial protein called dystrophin, which is vital for muscle cell integrity. This condition results in severe muscle wasting, loss of mobility, respiratory difficulties, and cardiac issues. Currently, there is no cure for DMD, but ongoing research seeks potential therapies to manage symptoms and improve the quality of life for affected individuals.
Becker Muscular Dystrophy (BMD) is a genetic disorder similar to Duchenne Muscular Dystrophy (DMD) but generally milder in its progression. It is caused by mutations in the dystrophin gene, leading to reduced production of the dystrophin protein in muscle cells. BMD typically has a later onset, with symptoms appearing in adolescence or adulthood. While muscle weakness and wasting occur in BMD, individuals with this condition often have a longer and more variable course of the disease compared to DMD. Treatment focuses on symptom management, and some therapies may help improve muscle function and quality of life.
Congenital Muscular Dystrophy (CMD) is a group of rare genetic disorders characterized by muscle weakness and poor muscle tone present from birth or early infancy. Unlike some other forms of muscular dystrophy, CMD often involves a variety of additional health issues, including developmental delays, joint contractures, and cognitive impairment. CMD is caused by mutations in various genes, impacting proteins essential for muscle and tissue function. Treatment aims to manage symptoms and improve quality of life, and the specific approach depends on the type and severity of CMD.
Distal Muscular Dystrophy (DMD) is a subgroup of muscular dystrophy characterized by muscle weakness and wasting, primarily affecting the muscles farthest from the center of the body, such as those in the hands and feet. DMD often has a later onset in adulthood and progresses slowly. Various subtypes exist, each associated with specific gene mutations. Treatment focuses on symptom management and supportive care, and the prognosis varies depending on the subtype and severity of the condition.
Emery-Dreifuss Muscular Dystrophy (EDMD) is a rare genetic disorder characterized by muscle weakness and wasting, joint contractures, and heart problems. It typically has an early onset, with symptoms appearing in childhood or adolescence. EDMD is caused by mutations in specific genes that affect the structure and function of muscle and heart cells. Treatment focuses on managing symptoms and may include physical therapy and cardiac monitoring. Early intervention and regular medical care are crucial for individuals with EDMD to address both muscle and cardiac issues.
Facioscapulohumeral Muscular Dystrophy (FSHD) is a relatively common genetic disorder characterized by muscle weakness and wasting, particularly in the face, shoulders, and upper arms. FSHD typically has an onset in adolescence or early adulthood. It is caused by a genetic mutation that affects muscle cell function. Although FSHD varies in severity, it generally progresses slowly. There is no cure, but management strategies may include physical therapy and assistive devices to improve mobility and quality of life. Regular medical monitoring is essential for individuals with FSHD to address their specific needs.
Limb-girdle Muscular Dystrophy (LGMD) is a group of rare genetic disorders characterized by muscle weakness and wasting, primarily affecting the muscles around the hips and shoulders (limb-girdle muscles). LGMD typically has an onset in adolescence or adulthood and varies in severity depending on the specific subtype and genetic mutation. It is caused by mutations in various genes involved in muscle function. Treatment focuses on managing symptoms and maintaining mobility through physical therapy and assistive devices. LGMD is progressive, and ongoing medical care is essential to address its challenges.
Myotonic Dystrophy (DM) is a genetic disorder characterized by muscle weakness, myotonia (prolonged muscle contractions), and a range of other symptoms that can affect multiple systems in the body. It is caused by mutations in specific genes that disrupt normal muscle function and can impact various organs, including the heart, eyes, and brain. DM typically has two main types: DM1 and DM2, each with its unique genetic cause and symptoms. There is no cure, and treatment focuses on managing symptoms and providing supportive care. Regular medical monitoring is essential for individuals with myotonic dystrophy to address the complexities of the condition.
Oculopharyngeal Muscular Dystrophy (OPMD) is a rare genetic disorder characterized by muscle weakness, primarily affecting the muscles involved in eye movement and swallowing (ocular and pharyngeal muscles). OPMD typically begins in adulthood, often in one's 40s or 50s. It is caused by mutations in specific genes that disrupt muscle cell function. Symptoms may include droopy eyelids, difficulty swallowing, and weakness in limb muscles. There is no cure, but treatment focuses on managing symptoms and providing support for swallowing and mobility issues. Regular medical monitoring is important to address the specific needs of individuals with OPMD.
Public Charitable Trust Reg. No. 3615 (India) ©Copyright 2016 by SEVA Trust UK All rights reserved.
Website Designed by AV Web Solution